Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy
- PMID: 9421204
- DOI: 10.3181/00379727-217-44202
Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy
Abstract
Despite nearly six decades of epidemiological studies, meta-analyses, and reviews, there is still considerable controversy in the literature about the question, does postmenopausal estrogen administration increase the risk of breast cancer? In an effort to resolve the controversy, a number of animal, biochemical, and clinical investigative studies in this field have been reviewed. The following summary formulation is proposed: 1. Administration of estrogen is inherently capable of promoting the growth of breast cancer, and therefore of increasing the incidence of clinical breast cancer. 2. Human response to estrogen is like that of the low-cancer-incidence strains of mice studied by Lacassagne, in that large doses and prolonged administration are required to induce clinical breast cancer. 3. The blood levels of estradiol produced by the usual doses of postmenopausal estrogen are relatively low, equivalent to those of the follicular phase of the menstrual cycle. These levels may be near the threshold for producing breast-cancer-promoting effects; therefore, the tumor response will vary greatly in different populations, depending on genetic susceptibility factors: a. The prevalence of a family history of premenopausal breast cancer in a first-degree relative. b. The prevalence of abnormal BRCA1, BRCA2, and p53 genes. c. The prevalence of increased 16 alpha-hydroxylation of estradiol. d. The prevalence of smokers who are slow acetylators. 4. Consumption of alcohol (5 grams or more daily) along with the postmenopausal estrogen administration results in elevation of blood estradiol levels to values equivalent to those of the periovulatory peak of the menstrual cycle, which may be well above the threshold for producing breast-cancer-promoting effects in all women. The risk for cancer will therefore be uniformly increased in women who use alcohol and take estrogen. 5. Increased risk of breast cancer from postmenopausal estrogen administration can be eliminated by taking two synergistic steps: a. Eliminating alcohol consumption, or at least keeping it well below an average of 5 grams daily (equivalent to 2/3 ounce of whiskey or 3 ounces of wine). b. Diminishing the capacity to 16 alpha-hydroxylate estradiol, either through pharmacological agents such as indole-3-carbinol or through increased consumption of cruciferous vegetables. It is concluded that despite the inherent ability of postmenopausal estrogen therapy to increase the risk of breast cancer in theory, the increased risk can be eliminated in practice by minimizing or eliminating consumption of alcohol and ingesting pharmacological or dietary agents that reduce the 16 alpha-hydroxylation of estradiol.
Similar articles
-
Moderate alcohol consumption and estrogen levels in postmenopausal women: a review.Alcohol Clin Exp Res. 1998 Aug;22(5):994-7. doi: 10.1111/j.1530-0277.1998.tb03694.x. Alcohol Clin Exp Res. 1998. PMID: 9726268 Review.
-
Biotransformation of estradiol by explant culture of human mammary tissue.Steroids. 1991 Jan;56(1):37-43. doi: 10.1016/0039-128x(91)90113-a. Steroids. 1991. PMID: 2028481
-
Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism.Proc Soc Exp Biol Med. 1998 Jan;217(1):6-16. doi: 10.3181/00379727-217-44199. Proc Soc Exp Biol Med. 1998. PMID: 9421201 Review.
-
Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes.Proc Soc Exp Biol Med. 1998 Mar;217(3):322-6. doi: 10.3181/00379727-217-44239. Proc Soc Exp Biol Med. 1998. PMID: 9492342
-
Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.Breast Cancer Res Treat. 2010 Jan;119(2):463-74. doi: 10.1007/s10549-009-0407-0. Epub 2009 May 8. Breast Cancer Res Treat. 2010. PMID: 19424794
Cited by 21 articles
-
The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):237-248. doi: 10.1007/s10911-018-9416-0. Epub 2018 Oct 18. J Mammary Gland Biol Neoplasia. 2018. PMID: 30338425 Free PMC article. Review.
-
Estrogen receptor alpha inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells.Oncotarget. 2016 Jun 28;7(26):39097-39107. doi: 10.18632/oncotarget.9772. Oncotarget. 2016. PMID: 27259243 Free PMC article.
-
Role of RUNX2 in Breast Carcinogenesis.Int J Mol Sci. 2015 Sep 2;16(9):20969-93. doi: 10.3390/ijms160920969. Int J Mol Sci. 2015. PMID: 26404249 Free PMC article. Review.
-
Role of estrogen in hepatocellular carcinoma: is inflammation the key?J Transl Med. 2014 Apr 8;12:93. doi: 10.1186/1479-5876-12-93. J Transl Med. 2014. PMID: 24708807 Free PMC article. Review.
-
Tracking progesterone receptor-mediated actions in breast cancer.Pharmacol Ther. 2014 Apr;142(1):114-25. doi: 10.1016/j.pharmthera.2013.11.010. Epub 2013 Nov 26. Pharmacol Ther. 2014. PMID: 24291072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Research Materials
-
Miscellaneous